Alprostadil associated with low molecular weight heparin to treat limb ischemia caused by SARS-CoV2

Detalhes bibliográficos
Autor(a) principal: Manhanelli Filho,Marcos Antonio Bonacorso
Data de Publicação: 2020
Outros Autores: Duarte Júnior,Eliud Garcia, Mariuba,Jamil Victor de Oliveira, Linardi,Fábio, Costa,José Augusto, Gali,Julio Cesar, Yoshida,Winston Bonetti, Gali Filho,Julio Cesar
Tipo de documento: Relatório
Idioma: eng
Título da fonte: Jornal Vascular Brasileiro (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492020000100623
Resumo: Abstract The current coronavirus pandemic has already taken a great toll globally, causing massive morbidity and mortality. One of its severe forms is a thrombophilic state that can damage several systems. This article reports the case of 60-year-old female patient who presented with mild flu symptoms, which turned out to be a SARS-CoV2 infection, and ended up developing arterial thrombosis with limb ischemia in a private care hospital in Sorocaba, São Paulo, Brazil. Considering this progression, we decided to intervene with low molecular weight heparin and Alprostadil, achieving a good clinical outcome. Our description aims to identify key points and clinical signs that offer evidence of the therapeutic window and a treatment option for coagulatory presentations of COVID-19.
id SBACV-1_821eb73541e29e13444655b1342a0087
oai_identifier_str oai:scielo:S1677-54492020000100623
network_acronym_str SBACV-1
network_name_str Jornal Vascular Brasileiro (Online)
repository_id_str
spelling Alprostadil associated with low molecular weight heparin to treat limb ischemia caused by SARS-CoV2COVID-19thromboembolismlimb ischemiaarterial thrombosisheparinAbstract The current coronavirus pandemic has already taken a great toll globally, causing massive morbidity and mortality. One of its severe forms is a thrombophilic state that can damage several systems. This article reports the case of 60-year-old female patient who presented with mild flu symptoms, which turned out to be a SARS-CoV2 infection, and ended up developing arterial thrombosis with limb ischemia in a private care hospital in Sorocaba, São Paulo, Brazil. Considering this progression, we decided to intervene with low molecular weight heparin and Alprostadil, achieving a good clinical outcome. Our description aims to identify key points and clinical signs that offer evidence of the therapeutic window and a treatment option for coagulatory presentations of COVID-19.Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)2020-01-01info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492020000100623Jornal Vascular Brasileiro v.19 2020reponame:Jornal Vascular Brasileiro (Online)instname:Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)instacron:SBACV10.1590/1677-5449.200072info:eu-repo/semantics/openAccessManhanelli Filho,Marcos Antonio BonacorsoDuarte Júnior,Eliud GarciaMariuba,Jamil Victor de OliveiraLinardi,FábioCosta,José AugustoGali,Julio CesarYoshida,Winston BonettiGali Filho,Julio Cesareng2020-11-25T00:00:00Zoai:scielo:S1677-54492020000100623Revistahttp://www.scielo.br/jvbhttps://old.scielo.br/oai/scielo-oai.php||secretaria@sbacv.org.br1677-73011677-5449opendoar:2020-11-25T00:00Jornal Vascular Brasileiro (Online) - Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)false
dc.title.none.fl_str_mv Alprostadil associated with low molecular weight heparin to treat limb ischemia caused by SARS-CoV2
title Alprostadil associated with low molecular weight heparin to treat limb ischemia caused by SARS-CoV2
spellingShingle Alprostadil associated with low molecular weight heparin to treat limb ischemia caused by SARS-CoV2
Manhanelli Filho,Marcos Antonio Bonacorso
COVID-19
thromboembolism
limb ischemia
arterial thrombosis
heparin
title_short Alprostadil associated with low molecular weight heparin to treat limb ischemia caused by SARS-CoV2
title_full Alprostadil associated with low molecular weight heparin to treat limb ischemia caused by SARS-CoV2
title_fullStr Alprostadil associated with low molecular weight heparin to treat limb ischemia caused by SARS-CoV2
title_full_unstemmed Alprostadil associated with low molecular weight heparin to treat limb ischemia caused by SARS-CoV2
title_sort Alprostadil associated with low molecular weight heparin to treat limb ischemia caused by SARS-CoV2
author Manhanelli Filho,Marcos Antonio Bonacorso
author_facet Manhanelli Filho,Marcos Antonio Bonacorso
Duarte Júnior,Eliud Garcia
Mariuba,Jamil Victor de Oliveira
Linardi,Fábio
Costa,José Augusto
Gali,Julio Cesar
Yoshida,Winston Bonetti
Gali Filho,Julio Cesar
author_role author
author2 Duarte Júnior,Eliud Garcia
Mariuba,Jamil Victor de Oliveira
Linardi,Fábio
Costa,José Augusto
Gali,Julio Cesar
Yoshida,Winston Bonetti
Gali Filho,Julio Cesar
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Manhanelli Filho,Marcos Antonio Bonacorso
Duarte Júnior,Eliud Garcia
Mariuba,Jamil Victor de Oliveira
Linardi,Fábio
Costa,José Augusto
Gali,Julio Cesar
Yoshida,Winston Bonetti
Gali Filho,Julio Cesar
dc.subject.por.fl_str_mv COVID-19
thromboembolism
limb ischemia
arterial thrombosis
heparin
topic COVID-19
thromboembolism
limb ischemia
arterial thrombosis
heparin
description Abstract The current coronavirus pandemic has already taken a great toll globally, causing massive morbidity and mortality. One of its severe forms is a thrombophilic state that can damage several systems. This article reports the case of 60-year-old female patient who presented with mild flu symptoms, which turned out to be a SARS-CoV2 infection, and ended up developing arterial thrombosis with limb ischemia in a private care hospital in Sorocaba, São Paulo, Brazil. Considering this progression, we decided to intervene with low molecular weight heparin and Alprostadil, achieving a good clinical outcome. Our description aims to identify key points and clinical signs that offer evidence of the therapeutic window and a treatment option for coagulatory presentations of COVID-19.
publishDate 2020
dc.date.none.fl_str_mv 2020-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492020000100623
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492020000100623
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1677-5449.200072
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)
publisher.none.fl_str_mv Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)
dc.source.none.fl_str_mv Jornal Vascular Brasileiro v.19 2020
reponame:Jornal Vascular Brasileiro (Online)
instname:Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)
instacron:SBACV
instname_str Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)
instacron_str SBACV
institution SBACV
reponame_str Jornal Vascular Brasileiro (Online)
collection Jornal Vascular Brasileiro (Online)
repository.name.fl_str_mv Jornal Vascular Brasileiro (Online) - Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)
repository.mail.fl_str_mv ||secretaria@sbacv.org.br
_version_ 1752126648833015808

Registros relacionados